Alumis Inc. (ALMS) shareholders
Close on Nov 18, 2026Market cap $568.87MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| James B. Tananbaum | 15,693,820 | 12.70% | 13D (active) amendment | Apr 1, 2026 |
| AyurMaya Capital Management Company, LP Joint filing with David E. Goel (12.30%) | 15,139,707 | 12.30% | 13D (active) amendment | May 14, 2026 |
| Deep Track Biotechnology Master Fund, Ltd. Joint filing with Deep Track Capital, LP (5.98%), David Kroin (5.98%) | 7,362,035 | 5.98% | 13G (passive) | Mar 30, 2026 |
| BlackRock, Inc. | 7,069,502 | 5.70% | 13G (passive) | Jun 30, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (5.50%) | 6,769,170 | 5.50% | 13G (passive) | Jun 30, 2026 |
| Srinivas Akkaraju | 6,345,219 | 5.40% | 13D (active) amendment | Jan 9, 2026 |
| Samsara BioCapital GP, LLC Joint filing with Samsara BioCapital, L.P. (5.00%), Srinivas Akkaraju (5.00%) | 4,801,370 | 5.00% | 13D (active) amendment | May 21, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ALMS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| AyurMaya Capital Management Company, LP | 15,139,707 | 11.70% | $426.03M | – | 100.00% |
| BlackRock, Inc. | 8,218,151 | 6.35% | $231.26M | +1,047,283 | 0.00% |
| FMR LLC | 6,769,170 | 5.23% | $190.48M | +5,795,388 | 0.01% |
| Deep Track Capital, LP | 6,348,558 | 4.90% | $178.65M | −424,037 | 2.60% |
| Samsara BioCapital, LLC | 6,345,219 | 4.90% | $178.55M | – | 14.67% |
| Foresite Capital Management V, LLC | 5,896,995 | 4.56% | $165.94M | – | 45.81% |
| Price T Rowe Associates Inc /Md/ | 5,199,838 | 4.02% | $146.33M | +1,913,085 | 0.01% |
| venBio Partners LLC | 4,528,408 | 3.50% | $127.43M | – | 24.53% |
| Foresite Capital Management VI LLC | 4,247,670 | 3.28% | $119.53M | – | 18.60% |
| Vanguard Capital Management LLC | 4,215,703 | 3.26% | $118.63M | +183,437 | 0.00% |
| Nextech Invest, Ltd. | 3,540,998 | 2.74% | $99.64M | – | 4.73% |
| Cormorant Asset Management, LP | 3,285,596 | 2.54% | $92.46M | −663,645 | 4.74% |
| Saturn V Capital Management LP | 2,915,443 | 2.25% | $82.04M | −286,632 | 11.76% |
| Octagon Capital Advisors LP | 2,830,700 | 2.19% | $79.66M | – | 7.16% |
| Jupiter Topco LLC | 2,355,122 | 1.82% | $66.24M | New | 0.03% |
| State Street Corp | 2,187,266 | 1.69% | $61.55M | +385,454 | 0.00% |
| Geode Capital Management, LLC | 2,168,517 | 1.68% | $61.03M | +250,102 | 0.00% |
| Mpm Bioimpact LLC | 2,019,020 | 1.56% | $56.82M | −367,509 | 3.46% |
| Baker Bros. Advisors LP | 2,012,500 | 1.55% | $56.63M | – | 0.28% |
| Sr One Capital Management, LP | 1,959,896 | 1.51% | $55.15M | – | 5.31% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 198 | 118M | 91.3% | 30 / 74 | 61 / 24 | 17M | 11M |
| Q1 2026 | 196 | 115M | 88.7% | 89 / 61 | 33 / 24 | 44M | 5M |
| Q4 2025 | 134 | 79M | 61.1% | 30 / 47 | 34 / 25 | 15M | 13M |
| Q3 2025 | 130 | 78M | 60.5% | 33 / 38 | 30 / 15 | 6M | 6M |
| Q2 2025 | 112 | 78M | 60.5% | 53 / 49 | 2 / 13 | 38M | 0M |
| Q1 2025 | 72 | 40M | 31.1% | 20 / 29 | 5 / 10 | 3M | 1M |
| Q4 2024 | 64 | 40M | 31.1% | 15 / 24 | 7 / 3 | 5M | 0M |
| Q3 2024 | 52 | 35M | 27.2% | 35 / 5 | 5 / 12 | 8M | 1M |
| Q2 2024 | 29 | 29M | 22.1% | 29 / 0 | 0 / 0 | 29M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
199 funds held ALMS in Q2 2026, 49% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ALMS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,139,756 | 2.43% | $88.35M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,020,285 | 1.56% | $56.85M | 0.07% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,369,916 | 1.06% | $38.55M | 0.26% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 1,103,470 | 0.85% | $31.17M | 0.35% | Jul 31, 2026 |
| Fidelity Stock Selector Small Cap Fund | 1,103,000 | 0.85% | $31.16M | 0.42% | Jul 31, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 1,088,300 | 0.84% | $30.62M | 0.31% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 977,098 | 0.75% | $27.50M | 0.03% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 946,500 | 0.73% | $26.74M | 1.22% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 863,916 | 0.67% | $24.41M | 0.07% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 682,035 | 0.53% | $19.19M | 0.12% | Jun 30, 2026 |
| Fidelity Series Small Cap Opportunities Fund | 633,300 | 0.49% | $17.89M | 0.38% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 620,000 | 0.48% | $13.39M | 0.25% | May 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 594,923 | 0.46% | $16.74M | 0.14% | Jun 30, 2026 |
| iShares Biotechnology ETF | 594,125 | 0.46% | $16.72M | 0.18% | Jun 30, 2026 |
| Fidelity Small Cap Growth K6 Fund | 572,460 | 0.44% | $16.17M | 0.35% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Martin Babler | President, CEO and Chairman, Director | 109,454 | 0.08% | Jan 28, 2026 |
| Sanam Pangali | Chief Legal Officer | 9,415 | 0.01% | Nov 4, 2026 |
| Mark Christopher Bradley | Chief Development Officer | 67,936 | 0.05% | Nov 4, 2026 |
| John R. Schroer | Chief Financial Officer | 23,924 | 0.02% | Nov 4, 2026 |
| Roy C. Hardiman | Chief Business & Strategy Ofcr | 213,511 | 0.16% | Nov 4, 2026 |
| David M. Goldstein | Chief Scientific Officer | 247,572 | 0.19% | Nov 4, 2026 |
| Jorn Drappa | Chief Medical Officer | 56,299 | 0.04% | Nov 4, 2026 |
| Derrick Richardson | SVP, People and Culture | 42,800 | 0.03% | Jul 31, 2025 |
| Sara Klein | Chief Legal Officer | 33,796 | 0.03% | Feb 20, 2025 |
| Srinivas Akkaraju | Director | 6,966,072 | 5.38% | Sep 9, 2026 |
| Patrick Machado | Director | 10,617 | 0.01% | Jul 2, 2026 |
| Lynn A. Tetrault | Director | 3,553 | 0.00% | Jul 2, 2026 |
| Sapna Srivastava | Director | 3,553 | 0.00% | Jul 2, 2026 |
| Zhengbin Yao | Director | 27,082 | 0.02% | Jul 2, 2026 |
| James B. Tananbaum | Director, 10% owner | 1,123,337 | 0.87% | Apr 3, 2026 |
| David E. Goel | Director, 10% owner | 10,645,966 | 8.22% | May 23, 2025 |
| AyurMaya Capital Management Company, LP | Director, 10% owner | 15,139,707 | 11.70% | May 23, 2025 |
| Alan Colowick | Director | 18,404 | 0.01% | Apr 3, 2025 |
| Foresite Capital Fund V, L.P. | 10% owner | – | – | Apr 3, 2026 |
| Foresite Capital Opportunity Fund V, L.P. | 10% owner | – | – | Apr 3, 2026 |
| Foresite Capital Opportunity Management V, LLC | 10% owner | 3,067,571 | 2.37% | Apr 3, 2026 |
| Foresite Labs Affiliates 2021, LLC | 10% owner | 0 | – | Apr 3, 2026 |
| Foresite Labs Fund I, L.P. | 10% owner | 2,908,332 | 2.25% | Apr 3, 2026 |
| Foresite Labs Management I, LLC | 10% owner | 4,247,670 | 3.28% | Apr 3, 2026 |
| Labs Co-Invest V, LLC | 10% owner | – | – | Apr 3, 2026 |
| Capital Fund VI LP Foresite | 10% owner | – | – | Apr 3, 2026 |
| Foresite Labs, LLC | 10% owner | 2,908,332 | 2.25% | Apr 3, 2026 |
| Foresite Capital Management V, LLC | 10% owner | – | – | Apr 3, 2026 |
| Capital Management VI LLC Foresite | 10% owner | 1,123,337 | 0.87% | Apr 3, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Sanam Pangali Chief Legal Officer | Nov 2, 2026 | Sale | −332 | $6.52 | $2.16K | 9,415 |
| Mark Christopher Bradley Chief Development Officer | Nov 2, 2026 | Sale | −623 | $6.52 | $4.06K | 47,910 |
| Jorn Drappa Chief Medical Officer | Nov 2, 2026 | Sale | −593 | $6.52 | $3.87K | 56,299 |
| David M. Goldstein Chief Scientific Officer | Nov 2, 2026 | Sale | −629 | $6.52 | $4.10K | 30,341 |
| John R. Schroer Chief Financial Officer | Nov 2, 2026 | Sale | −794 | $6.52 | $5.18K | 23,924 |
| Roy C. Hardiman Chief Business & Strategy Ofcr | Nov 2, 2026 | Sale | −652 | $6.52 | $4.25K | 207,094 |
| Srinivas Akkaraju Director | Sep 8, 2026 | Sale | −48,065 | $10.55 | $507.09K | 2,025,493 |
| Srinivas Akkaraju Director | Sep 8, 2026 | Buy | +273,290 | $10.63 | $2.91M | 2,298,783 |
| Srinivas Akkaraju Director | Sep 8, 2026 | Buy | +273,291 | $10.63 | $2.91M | 4,937,026 |
| Srinivas Akkaraju Director | Sep 8, 2026 | Sale | −48,066 | $10.55 | $507.10K | 4,663,735 |
| Srinivas Akkaraju Director | Sep 4, 2026 | Buy | +220,070 | $11.17 | $2.46M | 4,711,801 |
| Srinivas Akkaraju Director | Sep 4, 2026 | Buy | +220,070 | $11.17 | $2.46M | 2,073,558 |
| Roy C. Hardiman Chief Business & Strategy Ofcr | Aug 3, 2026 | Sale | −2,692 | $26.37 | $70.99K | 207,746 |
| David M. Goldstein Chief Scientific Officer | Aug 3, 2026 | Sale | −2,596 | $26.37 | $68.46K | 30,970 |
| Jorn Drappa Chief Medical Officer | Aug 3, 2026 | Sale | −2,447 | $26.37 | $64.53K | 56,892 |
| Mark Christopher Bradley Chief Development Officer | Aug 3, 2026 | Sale | −2,572 | $26.37 | $67.82K | 48,533 |
| Sanam Pangali Chief Legal Officer | Aug 3, 2026 | Sale | −1,364 | $26.37 | $35.97K | 9,747 |
| John R. Schroer Chief Financial Officer | Aug 3, 2026 | Sale | −3,282 | $26.37 | $86.55K | 24,718 |
| Sanam Pangali Chief Legal Officer | Jul 6, 2026 | Sale | −5,000 | $28.00 | $140.00K | 11,111 |
| Sanam Pangali Chief Legal Officer | Jul 6, 2026 | Option exercise | +5,000 | $5.06 | $25.30K | 16,111 |
| Zhengbin Yao Director | Jun 30, 2026 | Award | +3,553 | – | – | 27,082 |
| Srinivas Akkaraju Director | Jun 30, 2026 | Award | +3,553 | – | – | 3,553 |
| Sapna Srivastava Director | Jun 30, 2026 | Award | +3,553 | – | – | 3,553 |
| Lynn A. Tetrault Director | Jun 30, 2026 | Award | +3,553 | – | – | 3,553 |
| Patrick Machado Director | Jun 30, 2026 | Award | +3,553 | – | – | 3,553 |
| Jorn Drappa Chief Medical Officer | May 22, 2026 | Option exercise | +11,317 | $8.84 | $100.04K | 43,804 |
| Jorn Drappa Chief Medical Officer | May 22, 2026 | Option exercise | +15,535 | $5.06 | $78.61K | 59,339 |
| Foresite Labs Affiliates 2021, LLC 10% owner | Apr 1, 2026 | Other | −1,123,337 | – | – | 0 |
| Foresite Labs Affiliates 2021, LLC 10% owner | Apr 1, 2026 | Other | −1,176,470 | – | – | 0 |
| Foresite Labs Affiliates 2021, LLC 10% owner | Apr 1, 2026 | Other | +680,486 | – | – | 680,486 |
| Foresite Labs Affiliates 2021, LLC 10% owner | Apr 1, 2026 | Other | +1,123,337 | – | – | 1,123,337 |
| Capital Management VI LLC Foresite 10% owner | Apr 1, 2026 | Other | +1,123,337 | – | – | 1,123,337 |
| Capital Management VI LLC Foresite 10% owner | Apr 1, 2026 | Other | +680,486 | – | – | 680,486 |
| Capital Management VI LLC Foresite 10% owner | Apr 1, 2026 | Other | −1,123,337 | – | – | 0 |
| Capital Management VI LLC Foresite 10% owner | Apr 1, 2026 | Other | −1,176,470 | – | – | 0 |
| James B. Tananbaum Director, 10% owner | Apr 1, 2026 | Other | +1,123,337 | – | – | 1,123,337 |
| James B. Tananbaum Director, 10% owner | Apr 1, 2026 | Other | −1,176,470 | – | – | 0 |
| James B. Tananbaum Director, 10% owner | Apr 1, 2026 | Other | −1,123,337 | – | – | 0 |
| James B. Tananbaum Director, 10% owner | Apr 1, 2026 | Other | +680,486 | – | – | 680,486 |
| Srinivas Akkaraju Director | Jan 9, 2026 | Buy | +588,235 | $17.00 | $10.00M | 1,853,488 |
| Foresite Labs, LLC 10% owner | Jan 8, 2026 | Buy | +294,117 | $17.00 | $5.00M | 2,908,332 |
| Foresite Labs, LLC 10% owner | Jan 8, 2026 | Buy | +117,647 | $17.00 | $2.00M | 5,702,536 |
| James B. Tananbaum Director, 10% owner | Jan 8, 2026 | Buy | +117,647 | $17.00 | $2.00M | 5,702,536 |
| James B. Tananbaum Director, 10% owner | Jan 8, 2026 | Buy | +294,117 | $17.00 | $5.00M | 2,908,332 |
| Foresite Labs Fund I, L.P. 10% owner | Jan 8, 2026 | Buy | +294,117 | $17.00 | $5.00M | 2,908,332 |
| Foresite Labs Fund I, L.P. 10% owner | Jan 8, 2026 | Buy | +117,647 | $17.00 | $2.00M | 5,702,536 |
| Srinivas Akkaraju Director | Dec 5, 2025 | Buy | +64,969 | $8.95 | $581.47K | 1,143,845 |
| Srinivas Akkaraju Director | Dec 5, 2025 | Buy | +51,380 | $10.73 | $551.31K | 1,265,253 |
| Srinivas Akkaraju Director | Dec 5, 2025 | Buy | +70,028 | $10.01 | $700.98K | 1,213,873 |
| Srinivas Akkaraju Director | Dec 4, 2025 | Buy | +66,027 | $8.18 | $540.10K | 1,078,876 |
| Srinivas Akkaraju Director | Dec 3, 2025 | Buy | +100,000 | $7.75 | $775.00K | 1,012,849 |
| Srinivas Akkaraju Director | Dec 2, 2025 | Buy | +96,000 | $7.55 | $724.80K | 912,849 |
| Srinivas Akkaraju Director | Dec 1, 2025 | Buy | +86,350 | $7.46 | $644.17K | 816,849 |
| Srinivas Akkaraju Director | Nov 28, 2025 | Buy | +38,702 | $7.64 | $295.68K | 730,499 |
| Srinivas Akkaraju Director | Nov 26, 2025 | Buy | +48,537 | $7.64 | $370.82K | 691,797 |
| Foresite Labs Fund I, L.P. 10% owner | Nov 21, 2025 | Buy | +72,212 | $7.38 | $532.92K | 2,614,215 |
| Foresite Labs Affiliates 2021, LLC 10% owner | Nov 21, 2025 | Buy | +72,212 | $7.38 | $532.92K | 2,614,215 |
| James B. Tananbaum Director, 10% owner | Nov 21, 2025 | Buy | +72,212 | $7.38 | $532.92K | 2,614,215 |
| Srinivas Akkaraju Director | Nov 20, 2025 | Buy | +125,743 | $7.20 | $905.35K | 643,260 |
| Foresite Labs Affiliates 2021, LLC 10% owner | Nov 19, 2025 | Buy | +190,500 | $6.56 | $1.25M | 2,542,003 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Alumis's stock actually held short. Settlement fails (shares not delivered on time) peaked at 390,745 shares on Sep 2, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Sanampreet Pangali Officer | Jul 6, 2026 | 5,000 | $140.00K | Jul 6, 2026 | Stock Option Exercise |
See a number that looks wrong?